Recent Updates
Recently added Catalysts
DFTX Positive Sentiment

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Key Takeaway: Definium Therapeutics, a late-stage clinical biopharmaceutical company, will report its second quarter financial results for 2026 on August 6, 2026. The company aims to address psychiatric and neurological disorders with its therapeutics. A webcast will be held at 4:30 p.m. EDT to discuss these results and recent business highlights.

Market Sentiment Analysis

POSITIVE FACTORS

  • Definium Therapeutics is progressing in the late-stage clinical phase.
  • The company is focused on addressing significant psychiatric and neurological disorders.
  • The upcoming financial results may indicate positive growth and business highlights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~24 mo
Low dilution risk
Lead asset
DT120
Phase 3 · Major Depressive Disorder

Full Press Release Details

DUBLIN,July 30, 2026/PRNewswire/ --Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial results on Tuesday, August 11, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET.
The audio webcast may be accessed through the Investor Relations section of the Company's website atinvestor.keenova.comunder Events & Presentations or through thislink. To access the call through a conference line, participants canregister hereto receive a dial-in number and personalized PIN to participate in the call. Participants are advised to join 10 minutes prior to the scheduled start time. A replay of the webcast will be available following the event.

About Keenova

Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.
Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.
Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visitwww.keenova.com.
Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contacts

Investors

Media

SOURCE Keenova Therapeutics

Frequently Asked Questions

When will Definium Therapeutics report its Q2 2026 results?

Definium Therapeutics will report its Q2 2026 results on August 6, 2026.

What time is the webcast for the financial results?

The webcast will be held at 4:30 p.m. EDT.

What is the focus of Definium Therapeutics?

Definium Therapeutics develops therapeutics for psychiatric and neurological disorders.

How can I register for the webcast?

Listeners can register for the webcast via the provided link.

Last updated: Jul 30, 2026